Navigation Links
Ocular Therapeutix, Inc. Completes Series D Financing to Support Phase II Sustained Drug Delivery Clinical Trials
Date:2/2/2011

BEDFORD, Mass., Feb. 2, 2011 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing.  The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.  

The funding will be used to support Ocular Therapeutix's Phase II clinical trials across a variety of therapeutic areas.  The first trial will be conducted to reinforce safety and test efficacy of their first sustained drug delivery system, a moxifloxacin-loaded punctum plug.  Following, Ocular Therapeutix plans to initiate additional Phase II clinical trials for punctum plugs designed for the management of glaucoma, dry eye, and allergies, which combined represent markets over $3 billion.

"Ocular Therapeutix is developing an exciting platform of products that promises to meet prevalent medical and surgical needs within a variety ophthalmic disorders," commented Tara Butler, MD, Investment Director at Ascension Health Ventures.  "We are excited to be part of such promising technology."

This financing round comes on the heels of Ocular Therapeutix's sustained drug delivery proof of principle study, in which their moxifloxacin-loaded punctum plug achieved 100% retention in all patients as proven via tear fluid testing.  Additionally, the plug demonstrated sustained and favorable levels of moxifloxacin throughout the 10-day treatment period.  

"The support we are receiving from current and new investors highlights the success of our proof of principle study and our drug delivery platform technology as a whole," commented Amar Sawhney, President and CEO of Ocular Therapeutix.  "We look forward to the continued development and success of this program."

About Ocular Therapeutix, Inc.:

Founded in November 2006, Ocular
'/>"/>

SOURCE Ocular Therapeutix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
2. Sylentis Completes Phase I Trial with SYL040012 to Treat Elevated Intraocular Pressure and Glaucoma
3. Tekia Enters Into Distribution Agreement With Fritz Ruck/T-MED, Germany to Market Its Accommodative Intraocular Lens to Treat Presbyopia
4. Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
5. Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
6. Ocular Therapeutix, Inc. Appoints Two New Board Members
7. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
8. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
9. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
10. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
11. PLC Systems Completes Sale of TMR Business to Novadaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  MEI Pharma, ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at the inaugural Cantor Fitzgerald Healthcare ... time from Le Parker Meridien in ... can be accessed at www.meipharma.com . A replay will ...
(Date:7/1/2015)... July 1, 2015 Lupin ... Total Number of MPP Sub-licensees to Fourteen Companies ... Pool (MPP) announced the rapid expansion of its network of ... 50 projects to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin ... a promising new HIV medicine the MPP licensed from ViiV ...
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
Breaking Medicine Technology:MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3AVACEN Medical Patent Issued 2
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will ... the Twin Cities on Saturday, August 1, at Spring Lake Park High School. , ... more than $1 million worth of goods and services including free food, health services, ...
(Date:7/1/2015)... ... 2015 , ... Scoliosis is a disorder in which the normally straight vertical line of the ... 3 percent of the population, or an estimated 6 to 9 million people. While it ... ages of 10 and 15. Most types of scoliosis are more common in girls than ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... compensation law has just published a top ten list they hope will guide ... Click here to read it now. , More than 450 ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only ... a national chief nursing officer recruitment for Capital Health in ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... Research ... Examination Kit (Peek) smartphone app to test eyesight was just as accurate as those ... School of Hygiene and Tropical Medicine is responsible for the development of the test, ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3
... with golf tournament on August 4th, 2008 , ... Woburn, MA (PRWEB) ... that it will partner with Ovations for the Cure to promote awareness ... with the Driving for a Cure Golf Tournament on August 4th, 2008 ...
... A Women,s Cancer Initiative in Partnership with the Entertainment Industry ... Foundation,s Women,s Cancer Research Fund, ... Industry Foundation (EIF) announced today that Academy,Award(R) winning actress Gwyneth ... Fifth Avenue,s 2008 KEY TO THE CURE,campaign. KEY TO THE ...
... Senior Living,Inc. (NYSE: SRZ ) today updated ... webcast to discuss the Company,s 2007 financial results,and ... call will now be held on Friday, August ... issue its 2007 financial results and second-quarter 2008,preliminary ...
... action is largely perceived as a legitimate means ... shown industrial action can adversely affect those involved. ... at Griffith University, has examined the psychological impact ... while on strike from 2004-2006. , She ...
... women treated for breast cancer did not know that their ... same whether they undergo mastectomy or breast conserving surgery. Minority ... important factor of their treatment decision, according to a study ... women were also less likely to know about relative survival ...
... Preliminary results from Milliman,s,2008 Group Health Insurance Survey ... official rate of inflation but are lower than,premium ... renewal,increases of 8.5% for Health Maintenance Organizations (HMOs) ... trend toward lower,increases since peaking at 16.1% in ...
Cached Medicine News:Health News:SBLI and Ovations for the Cure Team up to Raise Cancer Awareness 2Health News:Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenue's 2008 KEY TO THE CURE Campaign 2Health News:Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenue's 2008 KEY TO THE CURE Campaign 3Health News:Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenue's 2008 KEY TO THE CURE Campaign 4Health News:Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data 2Health News:Psychological downside to strike action 2Health News:Minorities less likely to know about breast cancer treatment options 2Health News:Minorities less likely to know about breast cancer treatment options 3Health News:Milliman Survey Indicates Lower Health Insurance Rate Increases 2
Double-ended. Blades set at 45 and 90 degrees. Hexagonal handle....
3.5 mm blade. Round handle. Designated most popular model or size....
2 mm wide x 3 mm long, tapered handle. Angled 45 degrees. Round handle....
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
Medicine Products: